MX2020003845A - Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración. - Google Patents
Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.Info
- Publication number
- MX2020003845A MX2020003845A MX2020003845A MX2020003845A MX2020003845A MX 2020003845 A MX2020003845 A MX 2020003845A MX 2020003845 A MX2020003845 A MX 2020003845A MX 2020003845 A MX2020003845 A MX 2020003845A MX 2020003845 A MX2020003845 A MX 2020003845A
- Authority
- MX
- Mexico
- Prior art keywords
- prostate cancer
- resistant prostate
- androgens
- treatment
- metastatic castration
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 230000002280 anti-androgenic effect Effects 0.000 title abstract 2
- 239000000051 antiandrogen Substances 0.000 title abstract 2
- 230000000683 nonmetastatic effect Effects 0.000 title abstract 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 title 1
- 229940126534 drug product Drugs 0.000 abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 3
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 abstract 2
- 229950007511 apalutamide Drugs 0.000 abstract 2
- 229950001379 darolutamide Drugs 0.000 abstract 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 abstract 2
- 229960004671 enzalutamide Drugs 0.000 abstract 2
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/06—Buying, selling or leasing transactions
- G06Q30/0601—Electronic shopping [e-shopping]
- G06Q30/0607—Regulated
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Business, Economics & Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Accounting & Taxation (AREA)
- Finance (AREA)
- Strategic Management (AREA)
- Economics (AREA)
- Marketing (AREA)
- Development Economics (AREA)
- Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente descripción se describen métodos para tratar el cáncer de próstata no metastásico resistente a la castración mediante el uso de un producto farmacológico aprobado que comprende apalutamida, enzalutamida o darolutamida; también se describen 5 aquí productos farmacológicos que contienen apalutamida, enzalutamida o darolutamida, y métodos para vender u ofrecer para la venta un producto farmacológico antiandrógeno.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762572791P | 2017-10-16 | 2017-10-16 | |
US201862617745P | 2018-01-16 | 2018-01-16 | |
US201862630594P | 2018-02-14 | 2018-02-14 | |
PCT/US2018/030100 WO2019078920A1 (en) | 2017-10-16 | 2018-04-30 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003845A true MX2020003845A (es) | 2020-11-06 |
Family
ID=62165723
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003845A MX2020003845A (es) | 2017-10-16 | 2018-04-30 | Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración. |
MX2023005996A MX2023005996A (es) | 2017-10-16 | 2020-07-13 | Antiandrogenos para el tratamiento de cancer de prostata no metastasico resistente a la castracion. |
MX2023005997A MX2023005997A (es) | 2017-10-16 | 2020-07-13 | Antiandrogenos para el tratamiento de cancer de prostata no metastasico resistente a la castracion. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023005996A MX2023005996A (es) | 2017-10-16 | 2020-07-13 | Antiandrogenos para el tratamiento de cancer de prostata no metastasico resistente a la castracion. |
MX2023005997A MX2023005997A (es) | 2017-10-16 | 2020-07-13 | Antiandrogenos para el tratamiento de cancer de prostata no metastasico resistente a la castracion. |
Country Status (15)
Country | Link |
---|---|
US (6) | US10702508B2 (es) |
EP (1) | EP3697398A1 (es) |
JP (3) | JP7201694B2 (es) |
KR (2) | KR20240096623A (es) |
CN (1) | CN111479560A (es) |
AU (1) | AU2018351714A1 (es) |
BR (1) | BR112020007439A2 (es) |
CA (1) | CA3079135A1 (es) |
IL (1) | IL273919A (es) |
JO (1) | JOP20200076A1 (es) |
MX (3) | MX2020003845A (es) |
PH (1) | PH12020550267A1 (es) |
SG (1) | SG11202003402QA (es) |
TW (1) | TWI844512B (es) |
WO (1) | WO2019078920A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2708765C (en) | 2007-12-12 | 2019-01-08 | Miramar Labs, Inc. | Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy |
SI3305285T1 (sl) | 2012-09-26 | 2021-03-31 | Aragon Pharmaceuticals, Inc. | Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka |
JOP20200076A1 (ar) * | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals Inc | مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال |
US20200397756A1 (en) * | 2018-02-09 | 2020-12-24 | Kashiv Biosciences, Llc | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens |
WO2020144647A1 (en) * | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising apalutamide dispersed in apple sauce |
CN111249297B (zh) * | 2020-03-26 | 2021-11-30 | 南通大学 | 一种地高辛在制备用于治疗高睾酮血症的药物中的应用 |
MX2022014922A (es) * | 2020-05-27 | 2023-01-04 | Corcept Therapeutics Inc | Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos de cyp2c8. |
CN113304266A (zh) * | 2021-03-31 | 2021-08-27 | 上海市第五人民医院 | Usp16抑制剂在制备治疗或预防前列腺癌的药物中的应用 |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE550650A (es) | 1955-08-30 | |||
JPS4916937B1 (es) | 1970-01-21 | 1974-04-25 | ||
US3823240A (en) | 1970-10-06 | 1974-07-09 | Rhone Poulenc Sa | Fungicidal hydantoin derivatives |
GB1472467A (en) | 1974-04-19 | 1977-05-04 | Wyeth John & Brother Ltd | Thiohydantoins |
FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
DE2614831A1 (de) | 1976-04-06 | 1977-10-20 | Bayer Ag | 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
MC1220A1 (fr) | 1977-10-28 | 1979-07-20 | Hoffmann La Roche | Nouveaux derives d'imidazolidine |
CA1138334A (en) | 1977-10-28 | 1982-12-28 | Karl Bernauer | Pharmaceutical preparations containing certain urea derivatives |
JPS5492962A (en) | 1977-12-01 | 1979-07-23 | Wellcome Found | Thiohydantoin compound |
EP0004723A1 (en) | 1978-03-30 | 1979-10-17 | Beecham Group Plc | Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them |
FR2449448B1 (fr) | 1979-02-20 | 1983-05-27 | Inst Nat Radio Elements | Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation |
FI801184A (fi) | 1979-04-24 | 1980-10-25 | Hoffmann La Roche | Foerfarande foer framstaellning av imidazolidinderivat |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
JPS57197268A (en) | 1981-05-29 | 1982-12-03 | Sumitomo Chem Co Ltd | Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient |
DE3382406D1 (de) | 1982-04-08 | 1991-10-17 | Shell Int Research | Neue hydantoine, ihre herstellung und verwendung. |
US4473393A (en) | 1982-08-06 | 1984-09-25 | Buffalo Color Corporation | Pesticidal thiohydantoin compositions |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
JPS59210083A (ja) | 1983-05-13 | 1984-11-28 | Otsuka Chem Co Ltd | 1,3,4−チアジアゾ−ル−5−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤 |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
JPS6092285A (ja) | 1983-10-26 | 1985-05-23 | Shionogi & Co Ltd | イソオキサゾ−ル系環状尿素類 |
JPS6098878U (ja) | 1983-12-10 | 1985-07-05 | リズム時計工業株式会社 | 液晶表示装置 |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
JPS60239737A (ja) | 1984-05-14 | 1985-11-28 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料 |
EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
DE3604042A1 (de) | 1986-02-08 | 1987-08-13 | Hoechst Ag | Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
JPS649978A (en) | 1987-07-02 | 1989-01-13 | Shionogi & Co | Perfluoroalkylisoxazole derivative |
US4859228A (en) | 1987-07-16 | 1989-08-22 | Ici Americas Inc | Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
FR2619381B1 (fr) | 1987-08-13 | 1989-12-08 | Roussel Uclaf | Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
CA1331757C (en) | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
US5614620A (en) | 1988-03-30 | 1997-03-25 | Arch Development Corporation | DNA binding proteins including androgen receptor |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US6307030B1 (en) | 1988-04-15 | 2001-10-23 | The University Of North Carolina At Chapel Hill | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
JPH0219363A (ja) | 1988-07-06 | 1990-01-23 | Fujisawa Pharmaceut Co Ltd | イミダゾリジン誘導体 |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
DE3835168A1 (de) | 1988-10-15 | 1990-04-19 | Bayer Ag | N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
FR2656302B1 (fr) | 1989-12-22 | 1992-05-07 | Roussel Uclaf | Nouveau procede de preparation de l'anandron et derives de l'anandron. |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
USRE35956E (en) | 1991-01-09 | 1998-11-10 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
JP2845384B2 (ja) | 1991-11-14 | 1999-01-13 | キヤノン株式会社 | 画像処理装置 |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5346913A (en) | 1992-05-26 | 1994-09-13 | Rohm And Haas Company | N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
DE4316542C1 (de) | 1993-05-18 | 1994-07-21 | Schaefer Micomed Gmbh | Osteosynthesevorrichtung |
TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
FR2715402B1 (fr) | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
CA2181358A1 (en) | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
US6124211A (en) | 1994-06-14 | 2000-09-26 | Fsi International, Inc. | Cleaning method |
JPH089997A (ja) | 1994-06-28 | 1996-01-16 | Shimadzu Corp | 核酸合成法およびそれに用いる試薬キット |
US5691335A (en) | 1994-07-29 | 1997-11-25 | Suntory Limited | Imidazolidine derivative and use thereof |
FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
DE19540027A1 (de) | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
FR2741346B1 (fr) | 1995-11-16 | 1997-12-19 | Roussel Uclaf | Nouveau procede de preparation de derives phenylimidazolidine |
FR2741342B1 (fr) | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
US5554607A (en) | 1995-11-28 | 1996-09-10 | American Home Products Corporation | Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis |
TW418195B (en) | 1995-11-28 | 2001-01-11 | American Home Prod | 2-thioxo-imidazolidin-4-one derivatives |
EP0876354A1 (en) | 1995-11-28 | 1998-11-11 | American Home Products Corporation | 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5780435A (en) | 1995-12-15 | 1998-07-14 | Praecis Pharmaceuticals Incorporated | Methods for treating prostate cancer with LHRH-R antagonists |
FR2742749B1 (fr) | 1995-12-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques |
US6489163B1 (en) | 1996-05-08 | 2002-12-03 | Board Of Regents, The University Of Texas System | Ribozyme mediated inactivation of the androgen receptor |
JP3697320B2 (ja) | 1996-06-20 | 2005-09-21 | 株式会社日立製作所 | 光ファイバセンサ |
JP3860841B2 (ja) | 1996-08-30 | 2006-12-20 | ペプテック リミテッド | 持続性ペプチド放出製剤 |
US5726061A (en) | 1996-10-08 | 1998-03-10 | Smithkline Beechum Corporation | Method of diagnosing and monitoring colorectal cancer |
US7053263B2 (en) | 1996-10-15 | 2006-05-30 | The Regents Of The University Of California | Mouse models of human prostate cancer progression |
CN1126742C (zh) | 1997-02-03 | 2003-11-05 | 道农业科学公司 | 杀真菌化合物 |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6506607B1 (en) | 1997-12-24 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer |
AU4562799A (en) | 1998-06-15 | 2000-01-05 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
BR9914018A (pt) | 1998-09-22 | 2001-07-03 | Yamanouchi Pharmaceuticals Co | Derivado de cianofenila |
DE19940211A1 (de) | 1998-09-22 | 2000-03-23 | Degussa | Verfahren zur Herstellung von Imidazolidin-2,4-dionen |
AU1308400A (en) | 1998-10-30 | 2000-05-22 | G.D. Searle & Co. | Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors |
US6472415B1 (en) | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
WO2000044731A1 (en) | 1999-01-27 | 2000-08-03 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
US6350763B1 (en) | 1999-07-21 | 2002-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammation disease |
US6479063B2 (en) | 1999-12-27 | 2002-11-12 | Kenneth Weisman | Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis |
GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
BR0111188A (pt) | 2000-05-31 | 2003-06-10 | Tanabe Seiyaku Co | Inibidores de adesão de célula mediada por alfal beta2 |
US6482829B2 (en) | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
US20040077605A1 (en) | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
WO2002053155A1 (en) | 2000-12-30 | 2002-07-11 | Geron Corporation | Telomerase inhibitor |
FR2823209B1 (fr) | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
US6710037B2 (en) | 2001-05-01 | 2004-03-23 | Schering Corporation | Method of treating androgen-dependent disorders |
MXPA04002993A (es) | 2001-10-01 | 2004-07-15 | Bristol Myers Squibb Co | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios. |
WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
GB0200283D0 (en) | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
DE10218963A1 (de) | 2002-04-27 | 2003-11-20 | Aventis Pharma Gmbh | Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen |
TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
WO2004016758A2 (en) | 2002-08-15 | 2004-02-26 | Genzyme Corporation | Brain endothelial cell expression patterns |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
FR2845384B1 (fr) | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
FR2845385B1 (fr) | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
EP1558231A4 (en) | 2002-10-03 | 2010-09-08 | Cypress Bioscience Inc | DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS |
JP2006510600A (ja) | 2002-10-04 | 2006-03-30 | ラボラトワール フルニエ エス・アー | 2−チオヒダントインに由来する化合物及び治療におけるその使用 |
FR2850652B1 (fr) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
JP2004252175A (ja) | 2003-02-20 | 2004-09-09 | Kyocera Mita Corp | 現像装置、画像形成装置および現像剤の回収方法 |
CA2526387A1 (en) | 2003-06-12 | 2004-12-23 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
EP1634874A4 (en) | 2003-06-12 | 2008-04-02 | Chugai Pharmaceutical Co Ltd | imidazolidine |
BRPI0411255A (pt) | 2003-06-12 | 2006-08-01 | Novo Nordisk As | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto |
TW200523252A (en) | 2003-10-31 | 2005-07-16 | Takeda Pharmaceutical | Pyridine compounds |
US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
EP1709152A4 (en) | 2003-12-15 | 2007-11-07 | Univ California | MOLECULAR SIGNATURE OF PTEN TUMOR SUPPRESSOR |
US8034548B2 (en) | 2003-12-19 | 2011-10-11 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies |
AU2005232526B2 (en) | 2004-02-24 | 2011-06-23 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies and compounds |
WO2005089752A2 (en) | 2004-03-15 | 2005-09-29 | Ptc Therapeutics, Inc. | Tetra-cyclic carboline derivatives for inhibiting angiogenesis |
EP1621539A1 (en) | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
EP1775289B1 (en) | 2004-08-03 | 2011-03-30 | Chugai Seiyaku Kabushiki Kaisha | Novel imidazolidine derivatives |
TW200621723A (en) | 2004-09-09 | 2006-07-01 | Chugai Pharmaceutical Co Ltd | Novel imidazolidine derivative and use thereof |
AU2005281797B2 (en) | 2004-09-10 | 2011-07-07 | Jagotec Ag | Tablets with site and time-controlled gastrointestinal release of active ingredient |
EP1868644A1 (en) | 2005-03-23 | 2007-12-26 | Pfizer Products Incorporated | Therapy of prostate cancer with ctla4 antibodies and hormonal therapy |
KR102481886B1 (ko) | 2005-05-13 | 2022-12-28 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
FR2889189A1 (fr) | 2005-07-28 | 2007-02-02 | Cerep Sa | Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1 |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
CN101032486B (zh) | 2006-03-08 | 2011-05-11 | 张宏 | 逆转唑类药物抗真菌活性多药耐药性的药用植物增效剂 |
CN101032483B (zh) | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
HUE032085T2 (en) | 2006-03-27 | 2017-09-28 | Univ California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor related diseases |
JP5350217B2 (ja) | 2006-03-29 | 2013-11-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ジアリールチオヒダントイン化合物 |
EP1891964A1 (en) | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
CN101528309A (zh) | 2006-08-25 | 2009-09-09 | 库伽尔生物科技公司 | 包括给予维生素d化合物和另外的治疗剂的治疗癌症的方法 |
KR20200125776A (ko) | 2006-08-25 | 2020-11-04 | 코우가 바이오테크놀로지, 인크. | 암을 치료하기 위한 방법 및 조성물 |
EP1905439A1 (en) | 2006-09-24 | 2008-04-02 | GPC Biotech AG | Second line treatment of metastatic hormone refractory prostate cancer using satraplatin |
JP4993996B2 (ja) | 2006-10-20 | 2012-08-08 | フクダ電子株式会社 | 輸液ポンプモニタリング装置 |
US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
TW201716385A (zh) | 2007-10-26 | 2017-05-16 | 加州大學董事會 | 二芳基乙內醯脲類化合物 |
AU2008325016A1 (en) | 2007-11-09 | 2009-05-14 | Novartis Ag | Corticosteroids to treat epothilone or epothilone derivative induced diarrhea |
JOP20090061B1 (ar) | 2008-02-11 | 2021-08-17 | Ferring Int Center Sa | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
US20140187641A1 (en) | 2012-08-23 | 2014-07-03 | Gtx | Estrogen receptor ligands and methods of use thereof |
RU2548918C2 (ru) | 2009-02-24 | 2015-04-20 | Медивэйшн Простейт Терапьютикс, Инк. | Специфические соединения диарилгидантоина и диарилтиогидантоина |
EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
ES2880354T3 (es) | 2010-02-24 | 2021-11-24 | Medivation Prostate Therapeutics Llc | Procesos para la síntesis de compuestos de diariltiohidantoína y diarilhidantoína |
MX345788B (es) | 2010-08-04 | 2017-02-15 | Pellficure Pharmaceuticals Inc * | Nuevo tratamiento del carcinoma de prostata. |
WO2012024255A2 (en) | 2010-08-16 | 2012-02-23 | Duke University | Camkk-beta as a target for treating cancer |
US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
WO2012142208A1 (en) | 2011-04-13 | 2012-10-18 | The Trustees Of The University Of Pennsylvania | Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof |
WO2012145330A1 (en) | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Fluorene-9-bisphenol compounds and methods for their use |
WO2012158884A1 (en) | 2011-05-17 | 2012-11-22 | Takeda Pharmaceutical Company Limited | Pharmaceutical compositions and methods for treating cancer |
BR112014002200A2 (pt) | 2011-07-29 | 2017-03-07 | Medivation Prostate Therapeutics Inc | tratamento de câncer de mama |
EP2744773B1 (en) | 2011-08-19 | 2016-11-02 | British Columbia Cancer Agency Branch | Fluorinated bisphenol ether compounds and methods for their use |
US20130079241A1 (en) | 2011-09-15 | 2013-03-28 | Jianhua Luo | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse |
KR102035361B1 (ko) | 2011-11-30 | 2019-11-08 | 아스트라제네카 아베 | 암의 병용 치료 |
ES2888425T3 (es) | 2012-02-24 | 2022-01-04 | Univ Chicago | Métodos y composiciones relacionados con el antagonismo del receptor de glucocorticoides y con el cáncer de próstata |
WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
FR2989357B1 (fr) | 2012-04-12 | 2016-02-05 | Allia | Conditionnement unique pour un ensemble sanitaire comprenant une cuvette de wc suspendu et un bati-support associe |
NZ717683A (en) | 2012-06-07 | 2018-04-27 | Aragon Pharmaceuticals Inc | Crystalline forms of an androgen receptor modulator |
CN109897004A (zh) | 2012-09-11 | 2019-06-18 | 麦迪威森前列腺医疗有限责任公司 | 恩杂鲁胺制剂 |
SI3305285T1 (sl) | 2012-09-26 | 2021-03-31 | Aragon Pharmaceuticals, Inc. | Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
KR101787225B1 (ko) | 2013-04-23 | 2017-10-18 | 제트엑스 파마 엘엘씨 | 단백질성 서브코트를 갖는 장용 코팅된 다중 미립자 조성물 |
KR20160058774A (ko) * | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
CA2932106A1 (en) | 2013-12-06 | 2015-06-11 | F. Hoffmann-La Roche Ag | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
CR20170218A (es) | 2014-12-05 | 2017-08-30 | Aragon Pharmaceuticals Inc | Composiciones anticancerígenas |
MA41108B1 (fr) | 2014-12-05 | 2021-03-31 | Aragon Pharmaceuticals Inc | Compositions anticancéreuses |
MA41107A (fr) | 2014-12-05 | 2017-10-10 | Aragon Pharmaceuticals Inc | Compositions anti-cancéreuses |
CN104857157A (zh) | 2015-05-12 | 2015-08-26 | 四川金堂海纳生物医药技术研究所 | 一种治疗子宫内膜增殖症的汤剂药物及制备方法 |
JOP20200076A1 (ar) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals Inc | مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال |
CA3128331C (en) * | 2019-01-30 | 2024-06-18 | Margaret K. YU | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
-
2018
- 2018-04-30 JO JOP/2020/0076A patent/JOP20200076A1/ar unknown
- 2018-04-30 SG SG11202003402QA patent/SG11202003402QA/en unknown
- 2018-04-30 JP JP2020541641A patent/JP7201694B2/ja active Active
- 2018-04-30 BR BR112020007439-0A patent/BR112020007439A2/pt unknown
- 2018-04-30 KR KR1020247018251A patent/KR20240096623A/ko unknown
- 2018-04-30 AU AU2018351714A patent/AU2018351714A1/en active Pending
- 2018-04-30 US US15/967,452 patent/US10702508B2/en active Active
- 2018-04-30 EP EP18724747.3A patent/EP3697398A1/en active Pending
- 2018-04-30 KR KR1020207013923A patent/KR20200070334A/ko not_active Application Discontinuation
- 2018-04-30 MX MX2020003845A patent/MX2020003845A/es unknown
- 2018-04-30 WO PCT/US2018/030100 patent/WO2019078920A1/en active Application Filing
- 2018-04-30 CA CA3079135A patent/CA3079135A1/en active Pending
- 2018-04-30 CN CN201880081345.0A patent/CN111479560A/zh active Pending
- 2018-05-02 TW TW107115158A patent/TWI844512B/zh active
-
2020
- 2020-04-12 IL IL273919A patent/IL273919A/en unknown
- 2020-04-14 PH PH12020550267A patent/PH12020550267A1/en unknown
- 2020-05-28 US US16/885,767 patent/US11491149B2/en active Active
- 2020-05-28 US US16/885,570 patent/US11160796B2/en active Active
- 2020-07-13 MX MX2023005996A patent/MX2023005996A/es unknown
- 2020-07-13 MX MX2023005997A patent/MX2023005997A/es unknown
- 2020-12-10 US US17/118,033 patent/US20210093620A1/en not_active Abandoned
-
2022
- 2022-07-13 US US17/863,967 patent/US20230022446A1/en active Pending
- 2022-12-22 JP JP2022205507A patent/JP2023030107A/ja not_active Withdrawn
-
2023
- 2023-11-22 US US18/517,512 patent/US20240100033A1/en active Pending
-
2024
- 2024-05-02 JP JP2024074713A patent/JP2024099817A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200070334A (ko) | 2020-06-17 |
PH12020550267A1 (en) | 2021-02-22 |
JP2024099817A (ja) | 2024-07-25 |
EP3697398A1 (en) | 2020-08-26 |
JP2020536965A (ja) | 2020-12-17 |
US11160796B2 (en) | 2021-11-02 |
US20230022446A1 (en) | 2023-01-26 |
JP7201694B2 (ja) | 2023-01-10 |
US20240100033A1 (en) | 2024-03-28 |
MX2023005997A (es) | 2023-06-08 |
US20220054468A9 (en) | 2022-02-24 |
CN111479560A (zh) | 2020-07-31 |
WO2019078920A1 (en) | 2019-04-25 |
MX2023005996A (es) | 2023-06-08 |
KR20240096623A (ko) | 2024-06-26 |
TWI844512B (zh) | 2024-06-11 |
AU2018351714A1 (en) | 2020-04-30 |
JOP20200076A1 (ar) | 2020-04-30 |
JP2023030107A (ja) | 2023-03-07 |
US20190111036A1 (en) | 2019-04-18 |
US11491149B2 (en) | 2022-11-08 |
BR112020007439A2 (pt) | 2020-10-27 |
IL273919A (en) | 2020-05-31 |
US10702508B2 (en) | 2020-07-07 |
SG11202003402QA (en) | 2020-05-28 |
TW201916878A (zh) | 2019-05-01 |
US20200352926A1 (en) | 2020-11-12 |
CA3079135A1 (en) | 2019-04-25 |
US20210093620A1 (en) | 2021-04-01 |
US20200360361A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003845A (es) | Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración. | |
WO2018140831A3 (en) | Tumor targeting conjugates and methods of use thereof | |
CR20200140A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
SG11201906554RA (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
WO2016070051A3 (en) | Combination therapy for treatment of disease | |
TW201613644A (en) | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor | |
SA519402288B1 (ar) | مركب بيريميدين واستخداماته الصيدلانية | |
EP3808367A3 (en) | Targeting aneurysm disease by modulating phagocytosis pathways | |
BR112019003577A2 (pt) | métodos de tratamento da semente e produtos resultantes | |
ECSP19075677A (es) | Compuesto macrocíclico y sus usos | |
BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
MX2022006768A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
SG10201908500UA (en) | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
MX2021007484A (es) | Compuestos nuevos y su uso en terapia. | |
PH12020551179A1 (en) | Methods for treating mitochondrial disorder | |
PH12021551223A1 (en) | Decarboxylase inhibitors for treating parkinson`s disease | |
GEP20217301B (en) | Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof | |
BR112017028012A2 (pt) | Terapia combinada com um conjugado anticorpo- fármaco anti-her2 e um inibidor de bcl-2 | |
PH12020550532A1 (en) | Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor |